(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €20.45 | 2.23% | 7.98% |
| ESSILORLUXOTTICA (EL.PA) | €209.70 | 2.05% | 6.3% |
| UCB (UCB.BR) | €143.60 | 0.97% | 3.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.23% Forward Dividend Yield and 7.98% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.
More news about LNA SANTE.
2. ESSILORLUXOTTICA (EL.PA)
2.05% Forward Dividend Yield and 6.3% Return On Equity
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.08.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 41.28. Meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.3%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 6, 2024, the estimated forward annual dividend rate is 3.95 and the estimated forward annual dividend yield is 2.05%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be oversold (<=20).
More news about ESSILORLUXOTTICA.
3. UCB (UCB.BR)
0.97% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.77.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 81.13. Meaning, the purchaser of the share is investing €81.13 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Yearly Top and Bottom Value
UCB’s stock is valued at €143.60 at 12:30 EST, under its 52-week high of €146.80 and way above its 52-week low of €65.40.
Sales Growth
UCB’s sales growth for the current quarter is 7.4%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 26, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 0.97%.
More news about UCB.
